glp 1 agonist natural sources Unlocking the multifaceted roles of GLP-1: Physiological functions and therapeutic potential Mapping the effectiveness and risks

RELIEVES THE 4 WORST GLP-1 SIDE EFFECTS IN ONE FORMULA Constipation that lasts 46 days

GLP-1RAs reduce events linked to atherogenic cardiovascular disease (especially ischemic stroke) and also renal outcomes (FLOW trial with semaglutide), with a limited effect on heart failure

In late April 2025, the FDA issued a key update regarding the use of compounded GLP-1 receptor agonists like semaglutide and tirzepatide

Additionally, several key clinical trial readouts delivered compelling data across multiple indications, for example (see Figure 1): Semaglutide: STEP-HFpEF (functional benefits in HFpEF), STEP-9 (pain reduction in knee osteoarthritis), STEP-10 (reversion to normoglycaemia in pre-diabetic, obese patients), ESSENCE (resolution of MASH, improvement in fibrosis) Tirzepatide: SUMMIT (risk reduction in HFpEF outcomes

Retatrutide works by activating GLP-1, GIP and glucagon receptors

Eli Lilly has just launched its newly approved GLP-1 product, Zepbound, in a direct-to-consumer approach